OncoMatch/Clinical Trials/NCT05693909

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

Is NCT05693909 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies SP-420 for beta thalassemia major anemia.

Phase 2RecruitingPharmacosmos A/SNCT05693909Data as of May 2026

Treatment: SP-420 — The goal of this clinical trial is to learn about SP-420 ability to remove iron from organs in subjects with transfusion-dependent β-thalassemia or transfusion-dependent low-risk myelodysplastic syndrome. The main questions it aims to answer are: * How efficient is SP-420 in cleaning iron from the liver? * How is the safety and tolerability of ascending doses of SP-420? Participants will: * Take medication three times weekly * Attend up to 20 site visits * Undergo MRI scans

Check if I qualify

Extracted eligibility criteria

Cancer type

Myelodysplastic Syndrome

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify